免疫调节剂Fingolimod治疗多发性硬化症的机制和研究进展

摘要

T淋巴细胞通过血脑屏障作用于髓鞘,引起髓鞘脱失是多发性硬化症(MS)发病机制的主要原因,而1-磷酸鞘氨醇(S1P)是影响淋巴细胞迁移的重要因素.Fingolimod作为第一种美国食品药品管理局批准的用于治疗复发缓解型MS的口服药物,其磷酸化后与S1P结构相似,相当于S1P的功能拮抗剂,可使淋巴细胞停留在淋巴结中,从而抑制免疫反应对髓鞘的破坏.%The T cells getting through the blood-brain barrier and attacking the myelin is the main patho-genesis of multiple sclerosis( MS ). Sphingosin-1-phosphate( SIP )is the important factor of the lymphocytes migration. Fingolimod is the first oral therapy approved by the Food and Drug Administration of the US for the treatment of relapsed and relieved MS. Phosphorylated Fingolimod is structurally similar to SI P, as the functional antagonist of SIP, can retain the lymphocytes in the lymph node, and protect the myelin from destruction.